Posted by Michael Wonder on 17 Mar 2026
Argo Biopharma receives FDA fast track designation for BW-20805, an investigational siRNA therapy for the treatment of HAE
16 March 2026 - Global Phase 2 open-label study in adult hereditary angioedema patients on-going, company on track for primary completion of study in the second half of 2026.
Argo Biopharmaceutical today announced that the US FDA has granted fast track designation to its novel siRNA therapy BW-20805, for the treatment of hereditary angioedema.
